Supect® (Radotinib) CML Chronic Myeloid Leukemia
"The drug called Supect® and made from radotinib (IY5511) by Il-Yang Pharmaceutical Co. in South Korea is the first anti-leukemia drug made in Asia.
This drug can also be administered to people who are non-responsive or resistant to current drugs as imatinib, nilotinib and dasatinib.
''A research team at Seoul St. Mary's Hospital's hematopoetic stem cell transplant center, led by professor Kim Dong-Wook, administered the new medicine, named IY5511, to 22 chronic myeloid leukemia patients from July 2008''...
Extract from Youhp
CLINICAL TRIALS
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
ARTICLES
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
February 20, 2020, Hematology Advisor
Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
February 3, 2020, British Journal of Haematology
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
March 27, 2019, Link Springer
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
December 31, 2018, Hindawi
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
March 25, 2018, PubMed
Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
December 10, 2017, Cancer Therapy Advisor
Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up
December 2017, ASH2017
Radotinib for CML Yields Better Responses Than Imatinib
November 8, 2017, Cancer Network
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
July 25, 2017, NCBI
Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia
September 22, 2017, PublMed
Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia
December 4, 2016, ASH 2016
In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients
February 10, 2016, Oncology Times
Radotinib Effective, Safe for Newly Diagnosed CML-CP
January 14, 2016, Cancer Therapy Advisor
Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
December 7, 2015, ASH 2015
The next big leukemia drug
November 23, 2015, The Korea Times
Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor
July 19, 2015, Clinical and experimental dermatology
Optimization of therapeutic doses of Radotinib for CML based on exposure-response relationship analyses
June 16, 2015, EHA
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells
June 12, 2015, PLOS
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
February 13, 2015, Leukemia
Radotinib in the treatment of chronic phase chronic myeloid leukemia patients
January 2015, haemetalogica.org
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
July 2014, Haematologica
Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial
December 10, 2012, Blood
Korean Pharmaceutical Company Develops New Leukemia Treatment
January 6, 2012, Arirang
Sale of new drug for myelogenous leukemia approved
January 5, 2012, Korea Times
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, OANA News
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, Yonhap News Agency
Radotinib approved in South Korea for CML
January 5, 2012, Biotech strategy blog
New Leukemia Drug Shows Promise
July 30, 2009, Korea Times
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
February 20, 2020, Hematology Advisor
Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
February 3, 2020, British Journal of Haematology
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
March 27, 2019, Link Springer
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
December 31, 2018, Hindawi
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
March 25, 2018, PubMed
Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
December 10, 2017, Cancer Therapy Advisor
Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up
December 2017, ASH2017
Radotinib for CML Yields Better Responses Than Imatinib
November 8, 2017, Cancer Network
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
July 25, 2017, NCBI
Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia
September 22, 2017, PublMed
Impact of Body Weight Adjusted Dose on Efficacy and Safety of Radotinib in Chronic Myeloid Leukemia
December 4, 2016, ASH 2016
In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients
February 10, 2016, Oncology Times
Radotinib Effective, Safe for Newly Diagnosed CML-CP
January 14, 2016, Cancer Therapy Advisor
Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
December 7, 2015, ASH 2015
The next big leukemia drug
November 23, 2015, The Korea Times
Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor
July 19, 2015, Clinical and experimental dermatology
Optimization of therapeutic doses of Radotinib for CML based on exposure-response relationship analyses
June 16, 2015, EHA
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells
June 12, 2015, PLOS
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
February 13, 2015, Leukemia
Radotinib in the treatment of chronic phase chronic myeloid leukemia patients
January 2015, haemetalogica.org
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
July 2014, Haematologica
Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial
December 10, 2012, Blood
Korean Pharmaceutical Company Develops New Leukemia Treatment
January 6, 2012, Arirang
Sale of new drug for myelogenous leukemia approved
January 5, 2012, Korea Times
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, OANA News
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, Yonhap News Agency
Radotinib approved in South Korea for CML
January 5, 2012, Biotech strategy blog
New Leukemia Drug Shows Promise
July 30, 2009, Korea Times
